35. Mazumder A, Eberlein TJ, Grimm EA, et al: Phase I study of the adoptive immunotherapy of 
human cancer with lectin-activated autologous mononuclear cells. Cancer 53:896-905, 1984. 
36. Rosenberg SA, Lotze MT, Muul LM, et al: Observation on the systemic administration of 
autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic 
cancer. N Eng J Med 313:1485-1492, 1985. 
37. Rosenberg SA, Lotze MT, Muul LM, et al: A progress report in the treatment of 157 patients with 
advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 
alone. N Eng J Med 316:1310-1321, 1986. 
38. Rosenberg SA, Spiess PJ, Laffeniere R: A new approach to the adoptive immunotherapy of cancer 
with tumor-infiltrating lymphocytes. Science 233:1310-1321, 1986. 
39. Topalian SL, Muul LM, Solomon D, et al: Expansion of human tumor infiltrating lymphocytes for 
use in immunotherapy trials. J Immunol Methods 102:127-141, 1987. 
40. Itoh K, Tolden AB, Balch CM. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into 
human metastatic melanomas. Cancer Res 46:3011-3012, 1986. 
41. Kradin RL, Boyle LA, Preffer FI: Tumor-derived interleukin-2-dependent lymphocytes in adoptive 
immunotherapy of lung cancer. Cancer Immunol Immunother 24:76-85, 1987. 
42. Rosenberg SA, Packard BS, Aebersold PM, et al: Use of tumor-infiltrating lymphocytes and IL-2 in 
the immunotherapy of patients with metastatic melanoma: A preliminary report. N Eng J Med 
319:1676-1680,1988. 
43. Topalian SL, Solomon D, Avis FP, et al: Immunotherapy of patients with advanced cancer using 
tumor-infiltrating lymphocytes and recombinant interleukin-2: A pilot study. J Clin Oncol 6:839-853, 
1988. 
44. Fisher B, Packard BS, Read EF, et al: Tumor localization of adoptively transferred indium-111 
labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol 7:250-261, 
1989. 
45. Miller AD, Buttimore C: Redesign of retrovirus packaging cell lines to avoid recombination feeding 
to helper virus production. Mol Cell Biol 6:2895-2902, 1986. 
46. Kasid A, Moreeki S, Aebersold P, et al: Human gene transfer: Characterization of human tumor- 
infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci 
USA 87:473, 1990. 
47. Rosenberg SA, Aebersold P, Cornetta K, et al: Gene transfer into humans: Immunotherapy of 
patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene 
transduction. N Engl J Med 323:570-578, 1990. 
48. Rosenberg SA, personal communication. 
49. Reusser P, Riddell SR, Meyers JD, et al: Cytotoxic T lymphocyte response to cytomegalovirus 
following human allogeneic bone marrow transplantation: Pattern of recovery and correlation with 
cytomegalovirus infection and decrease. Blood, in press. 
50. Riddell SR, Greenberg PD: The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and 
expand human antigen-specific T cells. J Immunol Methods 128:189-197, 1990. 
51. Riddell SR, Rabin M, Geballe A, et al:Human cytomegalovirus-specific cytotoxic T lymphocytes 
recognize infected cells in the absence of viral gene expression. J Immunol 146:2795-2804, 1991. 
52. Maddon PJ, Dalgliesh AG, McDougal JS, et al: The T 4 gene encodes the AIDS virus receptor and is 
expressed in the immune system and the brain. Cell 47:333-348, 1986. 
53. Plata F, Autran B, Pedroza-Martins et al: AIDS virus-specific cytotoxic T lymphocytes in lung 
disorders. Nature 328:348-351, 1987. 
54. Zucker-Franklin D, Cao Y: Megakaryocytes of human immunodeficiency virus-infected individuals 
express viral RNA. Proc Natl Acad Sci USA 86:5595, 1989. 
55. Folks TM, Kessler SW, Orenstein JM, et al: Infection and replication of HIV-1 in purified 
[632] 
Recombinant DNA Research, Volume 15 
